Ho, ho, ho! Gather ’round, my dear friends, as I tell you a tale of scientific discovery, as magical as the Northern Lights themselves. In the frosty realm of medical research, a team of diligent elves (or scientists, as they prefer to be called) have been investigating the effects of a combination therapy on retinal ischemia-reperfusion injury (RIRI), a condition as unwelcome as a lump of coal in a Christmas stocking.

The heroes of our tale are N-acetylserotonin (NAS) and aflibercept, two compounds as potent as Santa’s secret eggnog recipe. NAS, known for its ability to reduce RIRI by inhibiting the TLR4/NF-κB/NLRP3 signaling pathway, and aflibercept, an anti-VEGF drug used to treat a variety of eye diseases, teamed up like Rudolph and his reindeer pals to combat RIRI.

The elves created a model of RIRI by elevating the intraocular pressure, much like the pressure I feel when Christmas Eve is approaching! They used H&E staining to observe the pathological changes in the retinal tissue, and evaluated cell apoptosis by TUNEL. The expression of cleaved caspase-3 in the retina was detected by immunofluorescence and western blotting, while the levels of SOD, GSH-Px, and MDA in retinal tissue were measured by ELISA. The protein expression of cytoplasmic Nrf2, nuclear Nrf2, HO-1, Akt, and p-Akt was determined by western blotting.

The results were as delightful as a perfectly decorated Christmas tree! The combination therapy significantly alleviated retinal histopathological damage, decreased retinal thickness and the rate of retinal apoptosis, and downregulated protein expression and positive expression of cleaved caspase-3. It also upregulated the levels of SOD and GSH-Px and downregulated the level of MDA to inhibit oxidative stress. Finally, it increased the protein expression of cytoplasmic Nrf2, nuclear Nrf2, and HO-1 and the p-Akt/Akt ratio.

In conclusion, much like the joy of Christmas morning, the combination therapy with NAS and aflibercept attenuated RIRI. Its mechanism may be related to inhibiting apoptosis and oxidative stress and activating the Akt/Nrf2 pathway. So, let’s raise a glass of milk and cookies to these scientific elves and their wonderful discovery! Ho, ho, ho!

Ho ho ho! Gather ’round, my dear friends, as we delve into the magical world of finger ailments, much like the elves and I delve into our toy-making. Now, you might have heard of fingers clicking and locking, or even crepitus, much like the sound of reindeer hooves on a snowy rooftop. While these symptoms might seem as inseparable as Christmas and candy canes, it’s crucial to tell them apart, as they often hint at different diagnoses, just like different children’s letters to Santa.

The list of potential diagnoses is longer than my naughty or nice list! It includes the likes of trigger finger, metacarpophalangeal joint (MCPJ) arthritis, fractures or dislocations, extensor digitorum communis subluxation or dislocation, locked MCPJ, avascular necrosis of the metacarpal head, and Dupuytren’s disease. It’s like a Christmas stocking filled with medical terms!

Just as I check my list twice, a thorough clinical examination with the right special investigations can help the clinician make the correct diagnosis. And fear not, for just like a well-delivered Christmas gift, appropriate management of a confirmed diagnosis can bring about symptomatic improvement, spreading joy and relief, much like a well-decorated Christmas tree. Ho ho ho!

Ho ho ho! Gather ’round, my dear friends, as I, Santa Claus, share a tale from the far-off land of Nepal. This story, much like the diligent work of my elves, revolves around a study conducted in 2019, focusing on a rare but dangerous condition known as Retinoblastoma (RB) among the children of Nepal.

What’s the story, Santa? Well, my little helpers, this study was a grand collaboration of ophthalmologists from across the nation, much like how we collaborate to make toys for all the good children. They selected 27 RB centers and included all the children who were either newly diagnosed or undergoing treatment for RB. However, those who didn’t wish to participate or had already conquered RB were excluded, much like how Rudolph was once excluded from the reindeer games.

And what did they find, Santa? They found that out of 34 RB cases, 21 were undergoing treatment and 13 were newly diagnosed. Most of these cases were from Province 1 and belonged to the upper caste. The most common symptom was Leukocoria, followed by proptosis, red eye, and phthisis bulbi. Just like how we sometimes find a naughty child on our list, they found that more than 75% of patients presented at advanced stages D and E.

That sounds serious, Santa! Indeed, my dear elves. But just like how we always find a way to deliver presents on time, more than 90% of these patients received systemic chemotherapy, and 42.6% received transpupillary thermotherapy. However, the cost of RB treatment was found to be a whopping 521% of the nonfood expense of the family, making it unaffordable for almost all cases.

So, what’s the moral of the story, Santa? The moral, my dear friends, is that early diagnosis and appropriate treatment are key to saving life, sight, and eye. However, much like how we need to spread the joy of Christmas, there’s a need for community awareness programs against RB, active referral networks, and the establishment of chemotherapy centers with trained human resources to reduce loss of life, sight, and eye. Now, let’s get back to our workshop and continue spreading joy and happiness! Ho ho ho!